<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During a period of 9 years we used the pediatric BFM-NHL protocol for treatment of 14 adult patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or L3 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Ten of 14 patients obtained a complete remission including 5/8 with stage-IV disease or <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>After a median follow-up of 55 months none of these ten patients relapsed </plain></SENT>
<SENT sid="3" pm="."><plain>The projected survival after 8 years is 71% </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity was moderate, with one early <z:hpo ids='HP_0011420'>death</z:hpo>; a <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> occurred in four patients </plain></SENT>
<SENT sid="5" pm="."><plain>From our experience we conclude that the BFM-NHL protocol is very effective in adult patients, with a high cure rate and acceptable toxicity, even in advanced stages of disease </plain></SENT>
</text></document>